Home / Business and Economy / Banks Vie for $4.25B Deal in Radiopharma Acquisition
Banks Vie for $4.25B Deal in Radiopharma Acquisition
15 Oct
Summary
- Multiple banks are competing for a $4.25 billion debt financing.
- The financing supports Curium's acquisition of Lantheus Holdings Inc.
- JPMorgan Chase & Co. is leading the financing effort.
Multiple financial institutions are actively vying for a role in a substantial $4.25 billion debt financing arrangement. This significant funding is set to support the acquisition of Lantheus Holdings Inc., a prominent radiopharmaceutical company, by Curium. The deal is structured to be syndicated to a wider investor base sometime next year.
JPMorgan Chase & Co. is at the forefront of this financing initiative, serving as one of Curium's financial advisors. The bank's leadership underscores the strategic importance of this transaction within the competitive landscape of pharmaceutical acquisitions.
As of the current date, the competition among banks to join this financing highlights the high stakes and anticipated profitability of the Curium-Lantheus deal. The syndicated offering is expected to attract considerable investor interest once it moves forward.
